# Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration

> **NCT04864834** · PHASE3 · COMPLETED · sponsor: **Sandoz** · enrollment: 485 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **BIOLOGICAL:** SOK583A1 (40 mg/mL)
- **BIOLOGICAL:** Eylea EU (40 mg/mL)

## Key facts

- **NCT ID:** NCT04864834
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-12
- **Primary completion:** 2022-07-07
- **Final completion:** 2023-05-10
- **Target enrollment:** 485 (ACTUAL)
- **Last updated:** 2024-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04864834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04864834, "Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04864834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*